HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jean-Paul Remadi Olivier Baron Daniel Duveau Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Remadi, J.-P. Articles by Duveau, D. Search for Related Content PubMed PubMed Citation Articles by Remadi, J.-P. Articles by Duveau, D.

Ann Thorac Surg 1998;66:762-767
© 1998 The Society of Thoracic Surgeons

---

Original articles: Cardiovascular

Mitral valve replacement with the St. Jude medical prosthesis: a 15-year follow-up

^a Cardiovascular Surgery Unit and Department of Anesthesiology, The G and R Laënnec University Hospital, Nantes, France

Accepted for publication March 25, 1998.

Address reprint requests to Dr Remadi, Cardiovascular Surgery Unit, The G and R Laënnec Hospital, 44035 St Herblain, Nantes, France

Background. A retrospective study was conducted to analyze the results of St. Jude Medical mitral valve replacement.

Methods. From January 1979 to December 1989, 870 patients (54% women, 46% men; mean age, 55.8 ± 6.2 years) underwent mitral valve replacement with the St. Jude Medical prosthesis. Of these operations 616 were isolated mitral valve replacements and 254 were double valve replacements. Coronary artery bypass grafting was performed concomitantly in 55 patients (6.3%).

Results. Overall, early mortality was 5.05%, with 4.2% for the isolated mitral valve procedure and 7.08% for the double valve replacement. Follow-up at 15 years was complete in 859 patients (98.74%). Mean follow-up time was 93.5 months, for a total of 6,436 years. Actuarial survival at 15 years was 59.5% ± 5%, 60.5% ± 6%, and 56.9% ± 9%, for the entire group, the isolated mitral valve and double valve procedures, respectively. Multivariate analysis identified age, sex, hospital stay, and preoperative mitral regurgitation as independent prognosis factors for overall mortality. Of 606 patients alive at the latest follow-up, the New York Heart Association class improved significantly (from 67% class III/IV before the operation to 88% class I/II after the operation). All patients received warfarin to maintain an international normalized ratio between 3.5 and 4. The linearized rates (% per patient-year) of thrombosis, thromboembolism, and major hemorrhage were, respectively, 0.21, 0.75, and 0.94 for the entire group; 0.18, 0.67, and 0.88 for the isolated mitral valve operation; and 0.15, 0.92, and 1.08 for the double valve replacement. For the entire group the freedom from thrombosis and thromboembolism at 15 years was 98.1% ± 1% and 88% ± 4%, respectively. No case of structural dysfunction occurred. The freedom from paravalvular leak and endocarditis at 15 years was 95.3% ± 2% and 97.3% ± 2.4%, respectively. The probability of remaining free from reoperation at 15 years was therefore 95.6% ± 2.5%.

Conclusions. These results confirm that the St. Jude Medical valve is a reliable prosthesis with very low thrombosis and thromboembolism rates, allowing the use of a low dose of anticoagulation with an international normalized ratio of about 3.

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				J.-P. Remadi, O. Baron, C. Tribouilloy, J. C. Roussel, O. Al Habasch, P. Despins, J.-L. Michaud, and D. Duveau Bivalvular mechanical Mitral-Aortic valve replacement in 254 patients: Long-Term results--a 22-year follow-up Ann. Thorac. Surg., August 1, 2003; 76(2): 487 - 492. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				J. P. Remadi, O. Baron, C. Roussel, P. Bizouarn, A. Habasch, P. Despins, J. L. Michaud, and D. Duveau Isolated Mitral Valve Replacement With St Jude Medical Prosthesis : Long-Term Results: A Follow-Up of 19 Years Circulation, March 20, 2001; 103(11): 1542 - 1545. [Abstract] [Full Text] [PDF]

				J. L. Zellner, J. M. Kratz, A. J. Crumbley III, M. R. Stroud, S. M. Bradley, R. M. Sade, and F. A. Crawford Jr Long-term experience with the St. Jude medical valve prosthesis Ann. Thorac. Surg., October 1, 1999; 68(4): 1210 - 1218. [Abstract] [Full Text] [PDF]